" class="no-js "lang="en-US"> Biolojic Design - Medtech Alert
Tuesday, July 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Biolojic Design | Pharmtech Focus

Biolojic Design

About Biolojic Design

Biolojic Design

Biolojic Design is committed to curing patients by designing and developing a pipeline of revolutionary therapeutics. Powered by AI, Biolojic’s technology designs single and multi-specific antibodies precisely targeting predefined epitopes to execute novel biological programs. Focusing on cancer and autoimmune diseases, Biolojic develops a pipeline of antibodies that are designed to unlock the full potential of well-studied pathways.

Related Story

Appointments

 Biolojic Design Appoints Ronald Herbst

Biolojic Design Appoints Ronald Herbst, Ph.D., as Chief Scientific Officer

September 15 2022

Biolojic Design, a pioneer in the use of artificial intelligence (AI) in antibody design, today announced […]